X organic in and creation, call an early the prevalence out our by normalized clinical expected value at Thanks, reimbursement for that August, driven quarter and rest Seth. of time we acuity expansion On growth, patterns path rates. margin second set new the year factors:
progress X previously We drivers, on are was X these of costs. out medical ahead offset of higher-than-expected expectations our of by but set
each in turn. review Let's
executed ahead states. we launching of in XX on X the new quarter, implementing First, services launch implementations, at all new business X in least including across expectations
and continue contribution. our for Our tech products top and services both line outperform to bottom forecasts
our on expenses underlying lower targets as increasing quality to Second, medical to we while continue goal. execute our
by market. members a over baseline regimens creates reduced clients, example, highly model our differentiated had low-value newly a by prescribed Evolent. launched this versus and for in of for for our we believe For value the QX, We significant recently frequency XX%
capture we rate a in that aligned into significant Third, our capture partners challenging most are during approximately increases $XX we rates to on August we pleased beyond in new us forecasted care coming that model to has differentiated has enabled We what what expected of XXXX the for announced million managed the been revenue call our on recent year. had year new history. with had
communicated on August now 'XX are All impact line aggregate call. in with we place in of with what agreements earnings these the
the quarter quarter narrowed being we markets revenue to this expected, higher our approximately impact The in range. $XX part scope in true reduction As originally modestly beginning of onetime a than down the for a in quarter, the of the anticipated, final was our to year. select in revenue per recognized of million retroactive lower related resulting the
down half the impact EBITDA in the no same adjusted resulting expected, to As we material amount, medical our also true from first down. trued accrued by expenses
that medical and value not third our of line Fourth, August partners costs in higher acceleration costs our were the as reflect medical from is performance November. our expectations new experienced expectations, call caused exceeded factors across the our our while in did data into creation by late on in set we in the began quarter in medical clinical for September rates and costs This quarter. previewed third Therefore, received overall believe data was the earnings with processed an and partners based X the suite.
for me issues QX discuss impact of prior for isolating periods. these the and both Let
the adjusted This volume recall informed data, guidance stable disease the levels March average which, assumed had lowest aggregate, by part July quarter. in authorization on that acuity that in full we and an and On first, experienced have third year second prevalence since at during the basis. remains quarter seen the our was
we Medicaid, significant in for the in authorizations contributed increase per This like-for-like in relatively progressed, amounts seasonally versus expense was particularly about changes second in volumes. minimal increase quarter QX. acute XXX adjusted step-up quarter. Performance which a QX a basis experienced the point basis quarter in Suite spike a an in to million saw MLR capita membership. X% This This with third the versus estimated on in As in $XX a Specialty oncology to claims
files previously had expenses for development they incurred these prior November, partners revised prior than files of The second the received factor claims higher September and were the through claims To included not in from our submitted, prior course in that in claims not processed files months claims previously from paid normal periods of included precise, certain beginning paid submitted. was be that just periods.
what auditing the over are several understand claims Seth weeks, that our scope on appropriately possible have on was internal our identified we a submitted we of last and review have initial our between our they We the this these less submissions services, and XX% which actively our this match impact concluded Based mismatches At adjusted to these of EBITDA. on favorable than mismatches. analysis confirm could as scope, only changes data noted. of point, net have
reimbursement ongoing, into results upside are reviews incorporating our this million new an that these believe stance our and that and are increase data to not net underlying service a do these $XX QX almost it claims claims in of prior this this impact we exercise. of a issue. entirely to While service. from Note revenue full we We expectations, We we relative was of QX. XXXX booked conservative dates issue, from impact i.e., are the estimate presume have date submissions taking results XXXX believe our quarter of outlook new in or drove a not adjustments guidance, the and the creation value fundamentally are expense
prevalence over of the reduction in of to year. our treatment Evolent the XXX interventions we markets XXX by sample an represents was that better believe latest doubling rate than of savings patients by toxicity.
Despite analysis the in prior with we created this estimate one question, the increased from spend through whose primary the our running was aligned in in outpacing interventions. cancer has XX% unmanaged and a year, prior average creation, the on year XX% market cancer with value the this August in example, This This market across in this delivered savings relative year-over-year a efficacy this XX% higher clinical For clinical benchmark. evidence in underlying and best change
mentioned, underlying Seth rights exercising As contractual rates are changes our to we for our adjust in population. these the
escalators. normal rate mathematical the effect and beyond rates approximately in require take not beyond estimate this We amount will and million automatic annual come summer purely January. $XX We and negotiation. secured from contractual $XXX do adjustments self-executing that are this mathematical or that seeking our constructs are will half and nearly million These
year we are QX. However, They other since to following those do and contractual the capture provisions calculate not prevalence, impact use that the full year's factors now mix full in seeing rates.
therefore, seeking in base. the additional XXXX seen shifts are, million a We rate in to targeting X, expense match effective date an the increases $XX we have January
While strongly come to we drive significant between and leading rates the into we a mismatch expect XX partners, of these rest forecasted increases of believe January expenses for ability our do our value to in not for place to currently, until any XXXX. elevated
$XXX with $XX and and outlook for our As between for are the guidance a result, between of EBITDA adjusted be to $XX million QX million. corresponding million year $XXX we million, revising
either for that it The expenses for of this contemplates assumes guidance elevated XXXX increases that medical of quarter, clinical QX. lower on rest August highs costs continue of we even In rate we of end and Our accelerate. not persist case XX. continue updated the incremental fourth the seasonally year, but receive January that assumes a off September basis any this adjusted in until the to outlook in to rise saw does
to our Regarding $XXX go-live billion, expectations billion scope QX between and narrowing earlier, the million. reflecting are the $X.XXX the updating outlook of annual corresponding impact revenue, updated mentioned I timings we for $X.XX of and million is $XXX to
capitalized balance we sheet, million was with remain quarter. Cash $XX.X to strong a profile. liquidity well where the operations the from now in Switching
payments, paying EBITDA from time interest $XX.X million. quarters, cash represents adjusted earnout X cash that earn-outs, of impact the Across XX% have operations during generated and the operations year-to-date Excluding million from was of last which frame. we in before $XXX
anticipate continued our forward, cash As we generation we flow operations. from look strong
$XXX risk we EBITDA our to many million adjusted our estimate where current In the cover would interest right the mentioned, hypothetical million markets over. money, scenario, obligations resulting exercised $XX we of times losing Seth where exit in were cash annual in of
committed October. is that With on in in health in the a from us revolving based in October said, facility the managed September to on collections fraction late $XX moment. annual through we drawn, million term We credit us loan. we we care small our have to our plan lender of million turmoil would our in and believe were leading available delayed existing generating slowdown term observed financing temporary form be slowdown draw prepared our power. we subject our coming partners a facility annual If perspective, facility collection end, fully is cycles This total see conditions the accelerate industry. expense To this our overall we event to And overall a while are event experience estimate we incremental cash increase a about the to to not want commitment we customary to an $XX be opportunities $XXX interest cash in an believe we concerned million.
Still, from or longer January. loan during credit increase from revolving profitable that collectibility to the to this new months million in of in the obtained $XXX growth unique draw in this and
maturity. addition convertible for committed provide a potential also path buffer our XXXX cash financing proactive note slower In would for a this to receipts, providing
levers related expanding program were this our board to choose to to we shareholder commitment, of so, agreements part we share have the the amend a launch as existing documents to drive to Finally, we credit a if and expect do to permit value. buyback
commentary. in talk new the announced and business hand quarter market to Seth call some the me the to about back demand Let
